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Autoimmune disease includes a large spectrum of clini-
cally distinct entities that share a common etiology, a
misguided, self-directed immune response. Collec-
tively, they are major contributors to morbidity and
mortality. Normally, the body utilizes a number of stra-
tegies to avoid the pathologic consequences of autoim-
mune reactions, but these defenses may fail for a
combination of hereditary and environmental factors.
Infection has long been regarded as a common environ-
mental trigger of autoimmune disease. Our laboratory
has developed a mouse model of myocarditis induced
by Coxsackievirus B3 infection and demonstrated some
of the steps involved in the transition from an infect-
ion to an autoimmune disease. Such basic studies may
suggest improved treatment or preventive measures for
this group of diseases. Key words: Autoimmunity/B cell/
Chemokine/Coxsackievirus/Cytokine/Infection/Myocarditis/
Tcell. J Investig Dermatol Symp Proc 9:1 ^4, 2004
T
he autoimmune diseases represent a diverse family of
disorders with di¡erent clinical presentations but
with a common etiology that involves an immune
response to autologous antigens. It has been esti-
mated that there are at least 80 human diseases in
which autoimmune responses participate signi¢cantly as the initi-
al cause or as a contributor.The immune-mediated injury may be
localized in a single organ system, as occurs in the pancreatic islets
in Type I diabetes mellitus and in the central nervous system in
multiple sclerosis. Or the diseases may a¡ect a multitude of or-
gans, as seen in systemic lupus erythematosus. Although most of
the autoimmune-related diseases disproportionately strike wo-
men, persons of both sexes and all ages, races, and ethnic and
socio-economic groups are a¡ected.
THE BURDEN OFAUTOIMMUNE DISEASE
Most of the autoimmune diseases individually are rare, but col-
lectively they represent a major medical and public health pro-
blem. A recent report by a committee of the U.S. National
Institutes of Health suggests that 14 to 22 million persons in the
United States su¡er from one of these diseases. Because of their
chronic nature and their debilitating e¡ects, autoimmune diseases
exact high economic costs, estimated at $100 billion annually.
Several of the autoimmune diseases a¡ect women in their repro-
ductive years, so the impact on young families is particularly pro-
nounced.
Unfortunately, there is very little accurate information on the
incidence and prevalence of the autoimmune diseases. Several
years ago, our group undertook a detailed review of the pub-
lished literature (Jacobson et al, 1997).We identi¢ed all of the stu-
dies published between 1965 and 1995 that provided estimates of
the incidence of one of the autoimmune diseases. Reliable ¢gures
could be found for only 24 of them. Most of the studies were
carried out in North America or Western Europe and provided
no insight into the incidence of autoimmune diseases in the de-
veloping world. Using data from these reports, we estimated the
total number of incident cases of these 24 diseases in 1996 in the
United States to be 237,203 new cases, of which 172,695 occurred
in women and 64,506 in men. These numbers translate to esti-
mated incidence rates of 1.6 cases per 100,000 females and 0.5 cases
per 100,000 males. Put another way, we estimated that every ¢ve
years 1,186,015 new cases of an autoimmune disease will occur in
the United States, assuming that incidence rates remain constant.
The highest incidence rates were found for rheumatoid arthritis
and the two major autoimmune thyroid diseases, Graves’ disease
and Hashimoto’s thyroiditis. It was clear to us that all of these ¢g-
ures were gross underestimates of the incidence of autoimmune
disease in the United States. For example, the autoimmune dis-
eases a¡ecting the skin, such as psoriasis, dermatitis herpetiformis,
pemphigus and pemphigoid, were not included because no eligi-
ble epidemiologic studies were available.
Estimates of the prevalence of the autoimmune diseases are
equally problematic. For many of them, criteria for diagnosis are
unsettled and therefore many cases remain unclassi¢ed. Often
autoimmune diseases undergo periodic exacerbations and remis-
sions, so estimates of the extent of cases of a disease within a po-
pulation at a speci¢ed time may be misleading. In general, most
of the autoimmune diseases are chronic; cures are unusual, and
survival is generally measured in decades. Prevalence is thus high
despite relatively low annual incidence rates. In our study, we es-
timated that 8.5 million people in the United States, or 3.2% of
the population, were living with at least one of the 24 autoim-
mune diseases in 1996. Prevalence rates for women and men were
5.0% and 1.4%, respectively. Extrapolation from these ¢gures
gives the previously cited estimates for the prevalence of all of the
autoimmune diseases in the range of 5% to 8% of the U.S. pop-
ulation. To gauge the impact of the autoimmune diseases, one can
cite ¢gures from the SEER registries showing that approximately
9 million people in the United States su¡ered from cancer in 1997
and, according to the NCHS statistics, approximately 22 million
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people were a¡ected by heart disease. Furthermore, the preva-
lence of heart disease and most forms of cancer has declined in
this country whereas the prevalence of most of the autoimmune
diseases has steadily risen.
Although most are not considered life threatening, autoim-
mune diseases are a signi¢cant cause of mortality in the United
States. A recent study by Walsh and Rau estimated that there
were 11,687 U.S. deaths from one of the 24 autoimmune diseases
included in our earlier study in 1995 (Walsh and Rau, 2000).
These diseases were among the 10 leading causes of death for wo-
men in every age group up to 65 years.
As stated above, the majority of autoimmune diseases dispro-
portionately a¡ect women (Whitacre, 2000).This disparity is sub-
stantial in the case of the autoimmune thyroid diseases,
scleroderma, lupus, and Sj˛gren’s disease, in which about 80% of
patients are females. In other diseases, the di¡erence is smaller:
Females represent 60% to 75% of patients with multiple sclerosis,
myasthenia gravis, and rheumatoid arthritis. In contrast the
male-to-female ratio in sarcoidosis, in£ammatory bowel disease,
and type I diabetes mellitus is approximately one to one. In a
few diseases, such as ankylosing spondylitis, there is male pre-
dominance.
Many reports suggest marked di¡erences in the distribution of
autoimmune diseases among di¡erent racial and ethnic groups.
For example, in the United States and Great Britain, inhabitants
of African origin are believed to have much higher rates of sys-
temic lupus erythematosus than do their European-derived coun-
terparts, but they have a lower risk for type I diabetes and
multiple sclerosis. The highest rates for Type I diabetes and multi-
ple sclerosis are found among northern Europeans, especially
Finns, but equally high rates have also been described in isolated
areas of Sardinia. Some native American tribes have been re-
ported to have a high prevalence of scleroderma; other tribes, of
spondylarthropathies. Asian Americans living in Hawaii have one
of the lowest rates of Type I diabetes and multiple sclerosis, but
these rates are subject to change as the populations move to the
continental United States. It is therefore unclear how much these
di¡erences are based on genetic factors and how much on envir-
onmental in£uences, such as nutrition, infectious agents, occupa-
tional exposures, and social stress.
THE ETIOLOGYOFAUTOIMMUNE DISEASE
A principal function of the immune system is to defend against
infection. The problem is that the agents of infection are highly
diverse and frequently changing, with new infectious disorders
emerging regularly. It is now evident, moreover, that the respon-
sibility of the immune system is to recognize any foreign sub-
stance, living or dead, introduced into the body by a parenteral
route.The immune system therefore must be capable of recogniz-
ing virtually an unlimited range of molecules, many of which
will be found in the body of the host itself.When the immune
system recognizes self antigens, autoimmune disease can result.
Fortunately, the body manages a number of maneuvers to mini-
mize the risk that these autoimmune responses will be harmful.
Ehrlich epitomized these measures in his picturesque phrase,
‘‘horror autotoxicus,’’ or a fear of self-poisoning.
Measures to ensure tolerance to self may act at the central or
peripheral level (Kamradt and Mitchison, 2001). Central tolerance
is the process by which autoimmune progenitor cells are elimi-
nated by apoptosis before they enter the peripheral circulation.
In the case of T cells, deletion of potentially autoreactive clones
occurs in the thymus. Presumably, a similar process of negative
selection occurs for autoreactive B cells in the bone marrow. In
addition, B cells are given a ‘‘second chance’’ to avoid elimination
by receptor editing. Clonal deletion in the bone marrow and thy-
mus, however, is at best an imprecise process. Negative selection
requires that the autologous antigens be presented in the thymus
or bone marrow during critical steps of lymphocyte maturation.
The major blood group antigens and major histocompatibility
antigens are well represented, and T cells and B cells reactive to
these widely distributed selfantigens are essentially never found
(Dighiero and Rose, 1999). Organ-speci¢c antigens of the thyroid
gland and brain, on the other hand, are poorly represented in the
thymus and bone marrow, and therefore thyroid-reactive and
brain-reactive T cells are common in peripheral sites. It is thus re-
latively easy to initiate autoimmune responses to these tissues.
Peripheral tolerance is the process by which cells that escape
deletion in the thymus or bone marrow are controlled so that tis-
sue damage does not occur. A number of processes have been dis-
covered to rein in these dangerous cells in the periphery. They
include, ¢rst, anergy, the process whereby cells encountering an
antigen-speci¢c stimulus in the absence of costimulatory signals
become inactive and eventually may die by apoptosis. The neces-
sary costimulatory signals may be provided by tissue in£amma-
tion or infection, circumstances in which anergy is terminated
and autoimmunity may arise. A second mechanism is immuno-
logical ignorance, in which the self-reactive lymphocytes fail to
localize in the presence of their corresponding antigen. Generally,
chemokines and adhesion molecules determine patterns of lym-
phocyte migration (Von Andrian and Mackay, 2000). Local
injury therefore may be the occasion for breeching the wall
of ignorance. Finally, the immune system is subject to important
regulatory mechanisms. These include populations of T cells and
macrophages that directly or indirectly downregulate immune re-
sponses. If these mechanisms have been impaired, immune re-
sponses, including autoimmunity, may continue unabated and
progress to autoimmune disease.
On the basis of our understanding of normal immune re-
sponse, it is possible to envision the circumstances that favor de-
velopment of harmful autoimmunity (Rose, 2002a). First, a
genetic predisposition favors the development of autoimmune re-
sponses. In addition to many studies on experimental animals,
there is compelling evidence of the importance of genetics in
the etiology of autoimmune diseases in humans. It includes data
showing that identical twins are more likely to su¡er from the
same autoimmune disease than are fraternal twins. Relatives of
patients with autoimmune diseases are at greater risk for develop-
ing the same or another autoimmune disease. As a general state-
ment, it seems that about a third of this risk is inherited. For most
autoimmune diseases, it is likely that multiple genes are involved.
The most prominent genes are members of the major histocom-
patibility complex, a group of genes known to regulate immune
responses. Thus, there are clear associations of HLA with Type I
diabetes, in£ammatory bowel disease, rheumatoid arthritis, sys-
temic lupus erythematosus, and Graves’ disease. A number of
other immune-related genes are under active investigation for
their association with autoimmune diseases, especially genes in-
volved in the production of cytokines, cytokine receptors, che-
mokines, and other regulators of the immune response.
Nonheritable factors make up more than half of the risk of de-
veloping an autoimmune disease among humans. A portion of
the nonheritable risk is associated with the randomness built into
the immune system (Nossal, 2001). As previously explained, in
order to accomplish its task of recognizing any foreign intruder,
the immune system develops a nearly limitless number of recog-
nition structures, utilizing in part postgermline recombination,
reassortment, and hypermutation of variable-region genes. Thus,
even identical twins have di¡ering immune responses. Beyond
these stochastic di¡erences, however, there is persuasive evidence
that external factors participate in the instigation of human auto-
immune diseases (Davidson and Diamond, 2001). The best stu-
died external agents are drugs, such as procainamide, that can
trigger a lupus^like syndrome in genetically susceptible indivi-
duals. The causal role of these drugs is shown by the ¢nding that
the disease remits when the drug is discontinued and can be re-
initiated by drug re-administration. A number of other drug-
related autoimmune illnesses have been described, including he-
molytic anemias, thrombocytopenias, and leukopenias. Sunlight
2 ROSE JID SYMPOSIUM PROCEEDINGS
is known to produce exacerbations of lupus in SLE patients, and
a great deal of epidemiological evidence suggests that silica in-
creases the incidence of scleroderma.
Infectious agents are the most commonly putative triggers of
human autoimmune disease (Davidson and Diamond, 2001).
The classic example is streptococcal infection leading to the de-
velopment of rheumatic heart disease. Guillain^BarreŁ syndrome
has been associated with a number of bacterial and viral infec-
tions, and reactive arthritis follows a variety of gastrointestinal in-
fections. Epidemiological evidence associates Type I diabetes
mellitus with previous rubella and possibly with Coxsackievirus
B4. More than a dozen viral agents have been claimed to precipi-
tate the onset of multiple sclerosis, and a similarly long list of pu-
tative viral agents can be assembled for lupus. In fact, it seems
probable that a number of di¡erent infectious agents can give rise
to the same autoimmune disorder in genetically predisposed
individuals.
The mechanisms by which infectious agents may modulate the
autoimmune process is not clear. The most popular explanation
suggests molecular mimicry, the sharing of epitopes between the
infectious agent and cell tissues. It is true that autoantibody pro-
duction commonly follows viral infection, but there are very
few, if any, ¢rm examples of human diseases attributable to mo-
lecular mimicry (Rose and Mackay, 2000). A role for superanti-
gens of bacteria and viruses that activate an entire family of T
cells nonspeci¢cally has also been suggested. An alternative ex-
planation for the association of infection with autoimmune dis-
ease is the mobilization of endogenous antigens so that they are
presented by resident dendritic cells (Rose, 2000b). Dendritic
cells e⁄ciently present antigen-presenting cells to naive T cells.
BecauseTcells require a second, nonspeci¢c signal to rescue them
from anergy, the second stimulus can be presented by the infec-
tious process. For example, dendritic cells activated by infection
express the B.7 family of costimulatory molecules.
In order to develop greater insight into the mechanisms by
which infection can initiate a pathogenic autoimmune process,
we developed a model of Coxsackievirus B3^induced myocardi-
tis in mice (Rose and Baughman, 1998).We discovered that all of
the many strains of mice we infected developed an acute but self-
limited viral myocarditis. During the early stage of this disease,
infectious virus could be isolated. Although most strains of mice
recovered completely, a few strains progressed to a chronic, on-
going myocarditis in the absence of infectious virus. The myocar-
ditis was characterized by the production of heart-reactive
autoantibodies. Further investigations showed that these antibo-
dies are speci¢c for the cardiac isoform of myosin. On the basis
of this clue, we immunized mice with cardiac myosin, using as
controls mice immunized in the same manner with skeletal myo-
sin.We found that all of the mouse strains susceptible to ongoing
myocarditis following viral infection developed myocarditis by
immunization with cardiac myosin. Mouse strains that failed to
develop postviral myocarditis were not a¡ected by the immuni-
zation. The development of this autoimmune disease correlated
with the production of IgG-1 myosin-speci¢c autoantibodies,
and the lesions could be transferred to naive mice with CD4 T
cells. Thus, it has been possible to reproduce a postinfection auto-
immune disease by immunization with a well-de¢ned antigen. In
fact, the actual peptide sequence responsible for inducing myo-
carditis in several strains of rats and mice has been delineated.
In subsequent experiments, we addressed the question of why
only a few strains of mice go on to develop the autoimmune
myocarditis following viral infection whereas most mice recover
completely from the viral disease.We found that two of the in-
£ammatory cytokines produced early during initial viral infec-
tion are key in the progression to autoimmune myocarditis.
Administration of IL-1 or TNF-a to unresponsive mice directed
them to develop autoimmune myocarditis. Conversely, blocking
either IL-1 or TNF-a prevented the development of disease
in susceptible strains (Neumann et al, 1993). Recently, we found
that complement, another key component of the innate immune
response, is also required for the development of autoimmune
myocarditis and that complement C3d sparks the production of
IL-1 and TNF-a (Kaya et al, 2001). Unexpectedly, NK cells were
found to protect against the development of autoimmune myo-
carditis, so that depleting them rendered resistant strains suscepti-
ble to the disease (Fairweather et al, 2001). Following that clue, we
examined the role of IFN-g, a major product of stimulated NK
cells, and discovered that administration of anti-IFN-g or immu-
nization of mice de¢cient in IFN-g produces an especially severe
form of myocarditis, resulting eventually in dilated cardiomyopa-
thy (Afanasyeva et al, 2001a). Many of these mice developed
heart failure, functionally similar to the heart failure evident
in humans with dilated cardiomyopathy. Administration of
recombinant IFN-g protected against this life-threatening auto-
immune disorder.
The prominence of myosin-speci¢c IgG-1 antibodies in this
disease was at ¢rst quite puzzling because this isotype of IgG is
usually correlated with TH2 responses (Afanasyeva et al, 2001b).
We therefore examined the histologic picture of myocarditis
more closely and found that in severe cases eosinophils and giant
cells were plentiful. The levels of IgE rose during immunization.
The development of myocarditis in susceptible strains was pre-
vented by administration of anti-IL-4. Severe myocarditis in the
mouse thus exhibits the phenotype typical of a TH2 response.
The ¢ndings provide a note of caution regarding the general as-
sumption that organ-speci¢c autoimmune diseases are associated
with a TH1 response and that a TH2 response signi¢es recovery.
Clearly, TH1 and TH2 responses are involved in the ¢nal patho-
genic picture, because the disease is also prevented by depleting
IL-12 or using IL-12 receptor knockouts. At the same time, our
¢ndings show that IFN-g downregulates whereas IL-12 promotes
the autoimmune disease by an IFN-g-independent pathway.
Finally, we have been able to show that IL-10 plays a role in re-
covery from autoimmune myocarditis because depleting this in-
terleukin causes extension of the disease with extensive cardiac
¢brosis.
These experiments emphasize for the ¢rst time the importance
of innate immune response in determining the later course of an
autoimmune reaction following a viral infection. Although many
strains of mice develop myosin-speci¢c autoantibodies following
CB3 infection, most of these antibodies are low-a⁄nity IgM and
are probably harmless. Moreover, most are not speci¢c for the
cardiac isoform of myosin, but cross-react with skeletal and brain
myosin. Thus, the presence of a speci¢c autoimmune response to
cardiac myosin is a marker of a pathological autoimmune reac-
tion. The role of the virus in producing this antigenic stimulus
is debatable.We have found no direct evidence of molecular mi-
micry in the form of a shared sequence. To the contrary, immu-
nization with inactivated virus failed to induce an autoimmune
response. Moreover, strains of virus that failed to infect the heart
are ine¡ective in inducing autoimmune myocarditis, even though
the virus replicated profusely in the pancreas (Horwitz et al, 1998).
For these reasons, we suggest that the role of the virus is to liber-
ate or otherwise expose endogenous cardiac myosin rather than
to mimic a self antigen (Rose, 2000). The second, and equally cri-
tical, role of virus infection is to foster the production of those
cytokines or other modulators of the immune response that drive
the autoimmune reaction to a pathological outcome. Some of the
factors generated during the innate response, such as IL-1, TNF,
and complement, are required for the development of myocardi-
tis, whereas IFN-g is protective. IL-4 and IL-12 are also essential
for the development of autoimmune disease, and IL-10 is a pivo-
tal factor in recovery (Kaya et al, 2002).
TREATMENTAND PREVENTION OFAUTOIMMUNE
DISEASE
At present, treatment of autoimmune disease is directed to remedy-
ing the particular defect or modifying the entire immune response.
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If the autoimmune damage is relatively well circumscribed, it is
possible to replace the missing function. For example, administra-
tion of insulin to diabetics or thyroid hormone to patients with
Hashimoto’s disease will alleviate most signs of the disease. Re-
moval of the thyroid gland will remedy the hyperthyroidism of
Graves’ disease. Often, the rami¢cations of autoimmune damage
are widespread and systemic treatment is required. Antimetabo-
lites and steroids as treatments for lupus and rheumatoid arthritis
are examples where the immune response is globally suppressed.
Neither therapeutic approach is entirely satisfactory, and a new
approach is greatly needed (Rose, 2002b) whose goal is to termi-
nate the damaging aspects of the autoimmune response without
impairing the general immune defense. Immunizing with the T
cell receptor (TCR) or with the hypervariable portion of the
TCR might abort the pathogenic autoimmune response.This ap-
proach has been successful in a number of experimentally in-
duced autoimmune diseases, such as allergic encephalomyelitis
and experimental thyroiditis. In humans, unfortunately, it is
rarely possible to delineate the particular antigen responsible for
the initiation of an autoimmune disease. By the time a patient is
clinically ill, the autoimmune response has escalated and the in-
itiating antigen is no longer easily identi¢ed.
An intermediate step is to inhibit the mediators of the patho-
logic autoimmune response. The current success of agents to
block TNF illustrates the power of this approach (Davidson and
Diamond, 2001). On the other hand, many immunomodulators
have di¡erent e¡ects in di¡erent autoimmune diseases or even
di¡erent e¡ects in the same disease at di¡erent times. There is al-
ready some disturbing preliminary evidence that anti-TNF agents
may exacerbate multiple sclerosis or increase the production of
antinuclear antibodies. A whole new pharmacology of autoim-
mune disease will be necessary before physicians can safely and
reliably use these powerful medicines.
A major impetus for devising new therapies is the develop-
ment of biomarkers to determine inordinate susceptibility to dis-
ease before the process is too far advanced (Rose, 2002b). As our
understanding of the natural history of autoimmune disease
grows, it may be possible to intervene before the disease has had
its devastating, irreversible e¡ects. Primary prevention is the ulti-
mate goal of public health and achieves the greatest bene¢t for
the least cost. Early interventions include opportunities for abort-
ing or terminating the pathologic immune response or identify-
ing and eliminating the environmental trigger. A striking
example of success of the latter approach is the virtual disappear-
ance of rheumatic fever, once the leading cause of death among
young people in the United States, purportedly through the
prompt treatment or prevention of streptococcal infections. The
next few years promise to be a period of unparalleled progress
in alleviating the burden of autoimmune disease.
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